API SUPPLIERS

API Suppliers

4

US DMFs Filed

4

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

1

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

1

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

3

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

4

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Q BioMed

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

Details:

The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

Lead Product(s): Strontium-89 Chloride

Therapeutic Area: Musculoskeletal Product Name: Metastron

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Chengdu Syncor Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 07, 2022

ASK
US